ALK and non-small cell lung carcinoma: Although targeted therapies have redefined treatment options for patients with driver-mutated NSCLC [e.g., anaplastic lymphoma kinase (ALK)-rearranged, epidermal growth factor receptor (EGFR)-mutant NSCLC], these therapies are ineffective in patients whose tumors lack these genetic alterations (4).